Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Autophagy
    (3)
  • HDAC
    (3)
  • Apoptosis
    (2)
TargetMol | Tags By ResearchField
  • Cancer
    (2)
Filter
Search Result
Results for "

jnj 26481585

" in TargetMol Product Catalog.
  • Inhibitors & Agonists
    3
    TargetMol | All_Pathways
Quisinostat
JNJ-26481585
T6055875320-29-9
Quisinostat (JNJ-26481585) (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7.
  • $54
In Stock
Size
QTY
TargetMol | Citations Cited
Quisinostat dihydrochloride
Quisinostat 2HCl, Quisinostat (JNJ-26481585) 2HCl, JNJ26854165(Quisinostat) 2HCl, JNJ-26481585 2HCl
T6865875320-31-3
Quisinostat dihydrochloride (JNJ26854165(Quisinostat) 2HCl) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2.
  • $59
In Stock
Size
QTY
Quisinostat hydrochloride
JNJ26481585 hydrochloride
T2141531083078-98-1
Quisinostat (JNJ-26481585) hydrochloride is a potent and orally active pan-HDAC inhibitor (HDACi), with IC50 values ranging from 0.11 to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10, and HDAC11. It demonstrates extensive antitumor activity and can induce autophagy (autophagy) in neuroblastoma.
  • Inquiry Price
10-14 weeks
Size
QTY